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Effect of Anticomplement Agent K-76 eOOH in Hamster-te-Rat and 
Guinea Pig-to-Rat Xenotransplantation 
M. Tanaka. N. Murase. H. Miyazawa. Q. Yeo R. Manez. S. Todo. A.J. Demetris. M. Nomoto. W. Miyazaki. 
and T. E. Starzl 
THE anticomplement agent K-76 COOH (K76). which 
mainly inhibits C5 activation. has been effectively used 
to mitigate experimental immune complex glomerulone-
phritis and ulcerative colitis.1.2 The effectiveness of K76. 
alone or in combination with FK 506 and cyclophospha-
mide (CP). in preventing xenograft rejection was studied 
using the hamster-to-rat and guinea pig-to-rat heart trans-
plantation model. 
MATERIALS AND METHODS 
Inbred male Lewis rats weighing 200 to 250 g. outbred male Syrian 
hamsters weighing 100 to ISO g. and outbred Hartley guinea pigs 
weighing 250 to 300 g were obtamed from Charles River Labora· 
tories (Wilmington. Mass). Heterotopic abdominal heart trans· 
plantation was performed using the technique described by Ono 
and Lindsey.J Rejection was diagnosed by the cessation of heart 
beat by palpation. followed by direct inspection. 
K76 (donated by Otsuka Pharmaceutical Co. Ltd. Tokushima. 
Japan). suspended in normal saline and adjusted to pH 7.8. 
intramuscular FK 506 (Fujisawa Pharmaceutical Co. Osaka. Ja-
pan). and oral CP were used in this study. Treatment schedules for 
xenograft recipients are listed in the Table 1. In hamster·to-rat 
transplantation. K76 (200 mgtkg) was intravenously injected 30 
minutes before graft revascularization and administered every 12 
hours for the first 6 days after graftmg. Two mg.'kg;d of FK 506 was 
injected intramuscularly on days () to S. 1.0 mg;kg/d on days 6 to 30. 
and 0.5 mgtkg/d every other dav thereafter. CP was given at a daily 
dose of 5.0 mgtkg on days -[ to 7. In the guinea pig-to-rat 
transplantation. various doses of K76 (100 to 400 mg/kg) were 
given 30 minutes before rcvascularization as a smgle bolus injec· 
tion. An additional group of animals were pretreated with FK S06 
(LO mg/kg/d) and CP (7.5 mg/kg/d) for 10 days (day -10 to -1). 
The Mann-Whitney U test was used for statistical analysis of 
xenograft survival and P < .0 I was considered significant. 
The development of anti-hamster antibodies in rat recipients was 
studied by complement-dependent Iymphocytotoxic antibody assav 
using serially diluted serum samples (heat inactivated. 56°C. for 30 
minutes). and hamster lymphocytes as described previously.' Baby 
rabbit serum (Cedarlane Laboratories Ltd) was used as a source of 
complement. The cytotoxic antibody titer was defined as the 
highest serum dilution with more than SI % of cell lysis. 
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Table 1. Effect of K76 eOOH in Hamster-to-Rat and Guinea Pig-ta-Rat Heart Transplantation 
Treatment 
K76 FK 506 CP Mechan" 
Group (mg/kg/d) (mg/kg/d) Img/kg/d) Survival P 
Hamster to Rat 1 6 3.0 
2 400' 6 4.0 <.005" 
3 2.00 6 4.0 <.005' 
4 5.0 (d -1-7) 3 4.0 NS" 
5 2.0b 5.0 (d -1-7) 9 5.0 <.002' 
6 400' 2.00 4 4.5 =.01' 
7 400' 5.0 (d -1-7) 4 7.0 =.01" 
8 400' 2.00 5.0 (d -1-7) 7 61.0 <.005" 
Guinea Pig to Rat 9 10 0.17 
10 100 x 1 5 1.70 <.005"" 
11 200 x 1 10 10.15 <.0005"" 
12 300 x 1 5 4.00 <.005"" 
13 400 x 1 3 5.90 =.01"" 
14 200 x 2 6 18.09 <.005"" 
15 200c 1.0 (d -10 to - 1) 7.5 (d -10 to - 1) 5 24.00 <.005" 
"K76 (200 mg/kg) was Intravenously Inlected 30 minutes before gratt revasculanzatlon and continued every 12 hours for 6 days. 
"Fl< 506 was Intramuscularlv Inlected at doses of 2.0 mglkgld (d 0-5). 1.0 mglkgld (d 6-30\. and 0.5 mg/kg/d (every otner day. d 31-100). 
'K76 was qlven 30 minutes before revaSCUIanzatlon and every 6 to 12 hours atter T x. 
"Mlldian survival of groups 1 to 8 was e,pressed In days. and groups 9 to 15 .n hOurs. 
'Vs group 1 
""'" group 9. 
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RESULTS 
Hamster-to-Rat Transplantation (Table 1, Groups 1 to 8) 
Untreated heart grafts were rejected in 3 days. When K76. 
FK S06. or CP was used as a single therapy (groups 2 to 4) 
or when two of three drugs were combined (groups 5 to 7). 
graft survival was slightly prolonged to 4 to 7 days. In 
animals treated with K76. FK S06. and CPo graft survival 
was dramatically enhanced. with a median of 61 days (group 
8). In these animals. anti-hamster Iymphocytotoxic antibody 
titers rapidly increased during the first 5 days, from a 
normal of 25 to a high of 28. Subsequently titers returned to 
2" and remained low for more than 28 days. 
Guinea Pig-to-Rat Transplantation 
(Table 1, Groups 9 to 15) 
Guinea pig hearts were hyperacutely rejected within 0.27 
hours by untreated rats. K76 doses of 100 and 200 mg/kg 
resulted in prolonged heart graft survival of 1.70 and 1O.1S 
hours. respectIvely. However. higher doses of K76 caused 
animal death with a beating graft in b of 8 recipients 
(groups 12 and 13). Repeated doses of K76 further pro-
longed graft survival to 18.09 hours. with 83% of animal 
deaths with beating grafts (group 14). The addition of FK 
S06 and CP pretreatment to K76 resulted in further pro-
longation of survival to 24 hours (group IS). 
DISCUSSION 
In the hamster-to-rat model. rejection is mainly caused by 
rapidly increasing xenospecific antibodies and subsequent 
complement activation, whereas in the guinea pig-to-rat 
model. the rejection was believed to cause direct comple-
ment activation via the alternative pathway and result in 
hyperacute rejection. As shown in this study, K76 was 
dfective in prolonging the hamster and guinea pig xe-
nograft survival in rats by inhibiting both types of comple-
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ment activation. A pharmacokinetic study of K76 revealed 
that an intravenous dose of 200 mg/kg effectively depletes/ 
suppresses complement activity in normal rats. ACHSO and 
C3 level were reduced to less than 50% of the initial value 
for 6 hours. whereas the inhibition of CHSO was less 
dramatic and only 20% suppression was seen for 3.S hours. 
When K76 was injected every 12 hours for the first 6 days. 
there was little prolongation of hamster graft survival. The 
addition of FK S06 and low-dose CP to this treatment 
protected the hamster graft from a vigorous antibody 
reaction and led to prolonged survival. However, the results 
obtained with K76. FK506, and CP are inferior to those of 
previous studies. in which suppression of B-cell prolifera-
tion and inhibition of antibody production were obtained by 
higher doses of CP and FK S06. 
On the other hand, a single bolus intravenous injection of 
K76 induced prolonged guinea pig heart graft survival. 
which could not be achieved by FK 506 and CPo This 
remarkable effect of K76 is better than the previous reports 
using intraperitoneal K76 administration. 
These results suggest that complement inhibition using 
K76 is effective for xenotransplantation that is mainly 
mediated by direct complement activation, such as the 
guinea pig to rat. When xenograft rejection is mediated by 
xenospecific antibodies and classical pathway complement 
activation. as in the hamster-to-rat model, inhibition of 
antibody production may be more effective than K76 in 
preventing rejection. 
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